232 filings
8-K
ACGN
Aceragen Inc
16 Aug 23
Departure of Directors or Certain Officers
4:07pm
8-K
ACGN
Aceragen Inc
21 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
ACGN
Aceragen Inc
11 Jul 23
Other Events
5:06pm
8-K
ACGN
Aceragen Inc
30 May 23
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
4:30pm
8-K
ACGN
Aceragen Inc
4 May 23
Cost Associated with Exit or Disposal Activities
8:52am
8-K
sf239gcehef3vc
30 Mar 23
Departure of Directors or Certain Officers
4:51pm
8-K
m2juk7q719k8
6 Feb 23
Aceragen ANNOUNCES Recommendation of DaTA monitoring COMMITTEE in TERRA Study
9:49am
8-K
5um80
3 Feb 23
Entry into a Material Definitive Agreement
4:31pm
8-K
g1uzn
18 Jan 23
Regulation FD Disclosure
5:28pm
8-K
idtfsz1 nzbq
17 Jan 23
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
5:24pm
8-K
eyn9nnn
13 Jan 23
Departure of Directors or Certain Officers
8:30am
8-K
qasgu119y
11 Jan 23
Other Events
8:30am
8-K/A
o435vfdzx6k575 qxi
9 Dec 22
Other Events
4:49pm
8-K
oxn7pkq96ooc5
23 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
ewtbfmm4v5g 3fm
17 Nov 22
Material Modifications to Rights of Security Holders
5:20pm
8-K
6pw3w4cip iq
14 Nov 22
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:39pm
8-K
t16osx0v1y
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
4ykobf
28 Sep 22
Idera Pharmaceuticals Acquires Aceragen
4:29pm
8-K
9su9rnx9
9 Aug 22
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
12:00am
8-K
qbi66vn2x
24 Jun 22
Departure of Directors or Certain Officers
8:00am